NCT04535882 Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
| NCT ID | NCT04535882 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Showa Inan General Hospital |
| Condition | LRG Levels |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2020-10-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2020-10-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.
Eligibility Criteria
Inclusion Criteria: * Patients whom possible UC or Crohn disease was suspected Exclusion Criteria: * other autoimmune diseases * acute or chronic renal failure * chronic heart diseases * liver cirrhosis * cancer * acute or chronic infections * ischemic colitis * infectious colitis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04535882 clinical trial?
This trial is open to participants of all sexes, studying LRG Levels. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04535882 currently recruiting?
Yes, NCT04535882 is actively recruiting participants. Contact the research team at horiuchi.akira@sihp.jp for enrollment information.
Where is the NCT04535882 trial being conducted?
This trial is being conducted at Komagane, Japan.
Who is sponsoring the NCT04535882 clinical trial?
NCT04535882 is sponsored by Showa Inan General Hospital. The trial plans to enroll 300 participants.